<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17137</article-id><article-id pub-id-type="doi">10.7554/eLife.17137</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human <italic>ALK</italic> mutant neuroblastoma cell lines and xenograft models</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-58636"><name><surname>Wang</surname><given-names>Hui Qin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-27410"><name><surname>Halilovic</surname><given-names>Ensar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58637"><name><surname>Li</surname><given-names>Xiaoyan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58638"><name><surname>Liang</surname><given-names>Jinsheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58639"><name><surname>Cao</surname><given-names>Yichen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58640"><name><surname>Rakiec</surname><given-names>Daniel P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58641"><name><surname>Ruddy</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24283"><name><surname>Jeay</surname><given-names>Sebastien</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-86310"><name><surname>Wuerthner</surname><given-names>Jens U</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81894"><name><surname>Timple</surname><given-names>Noelito</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81895"><name><surname>Kasibhatla</surname><given-names>Shailaja</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58642"><name><surname>Li</surname><given-names>Nanxin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58643"><name><surname>Williams</surname><given-names>Juliet A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82990"><name><surname>Sellers</surname><given-names>William R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81893"><name><surname>Huang</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-55124"><name><surname>Li</surname><given-names>Fang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0497-4200</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Disease Area Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff3"><institution>Genomics Institute of the Novartis Research Foundation</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1069"><name><surname>Dang</surname><given-names>Chi Van</given-names></name><role>Reviewing editor</role><aff><institution>University of Pennsylvania</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>fli@tangotx.com</email> (FL);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>04</month><year>2017</year></pub-date><volume>6</volume><elocation-id>e17137</elocation-id><history><date date-type="received"><day>23</day><month>04</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>04</month><year>2017</year></date></history><permissions><copyright-statement>Â© 2017, Wang et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Wang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-17137-v1.pdf"/><abstract><p>The efficacy of ALK inhibitors in patients with <italic>ALK</italic>-mutant neuroblastoma is limited, highlighting the need to improve their effectiveness in these patients. To this end we sought to develop a combination strategy to enhance the antitumor activity of ALK inhibitor monotherapy in human neuroblastoma cell lines and xenograft models expressing activated ALK. Herein, we report that combined inhibition of ALK and MDM2 induced a complementary set of anti-proliferative and pro-apoptotic proteins. Consequently, this combination treatment synergistically inhibited proliferation of <italic>TP53</italic> wild-type neuroblastoma cells harboring <italic>ALK</italic> amplification or mutations <italic>in vitro</italic>, and resulted in complete and durable responses in neuroblastoma xenografts derived from these cells. We further demonstrate that concurrent inhibition of MDM2 and ALK was able to overcome ceritinib resistance conferred by MYCN upregulation <italic>in vitro</italic> and <italic>in vivo</italic>. Together, combined inhibition of ALK and MDM2 may provide an effective treatment for <italic>TP53</italic> wild-type neuroblastoma with <italic>ALK</italic> aberrations.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Li</surname><given-names>Fang</given-names></name></principal-award-recipient></award-group><funding-statement>The research was funded by Novartis, Inc., where all authors were employees at the time the study was conducted. The authors declare no other competing financial interests.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All in vivo studies were reviewed and approved by the Novartis Institutes of Biomedical Research Institutional Animal Care and Use Committee (IACUC) in accordance with applicable local, state, and federal regulations.If needed, a letter from the IACUC Chair can be provided to confirm that all in vivo studies were reviewed and approved by the Novartis IACUC.  Below is the contact of the Novartis IACUC Chair.CeCe Brotchie-Fine, MA, CPIAManager, Animal Welfare ComplianceIACUC Chair &amp; Animal Welfare OfficerT +1 617 871 5064M+1 617 834 4784Email: Candice.brotchie-fine@novartis.comNovartis Institutes for BioMedical Research, Inc.700 Main Street, 460 ACambridge, MA 02139  USA</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-17137-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>